Baseline clinical characteristics of patients with MM before the initial SARS-CoV-2 vaccination (cohort 1)
| Patient characteristic . | All patients (n = 93) . |
|---|---|
| Age, y | |
| Median (range) | 65 (44-84) |
| >75, n (%) | 7 (8) |
| Male sex, n (%) | 48 (52) |
| Race, n (%) | |
| White | 83 (89) |
| Non-White | 10 (11) |
| COVID-19 vaccine, n (%) | |
| BNT162b2 | 49 (53) |
| mRNA-1273 | 34 (37) |
| JNJ-78436735 | 10 (11) |
| R-ISS stage, n (%) | |
| I | 46/85 (54) |
| II | 24/85 (28) |
| III | 15/85 (18) |
| Involved heavy and/or light chain, n (%) | |
| IgG | 51 (55) |
| IgA | 16 (17) |
| κ | 61 (66) |
| λ | 24 (26) |
| Nonsecretory | 1 (1) |
| Median monoclonal protein (range), g/dL | 0.05 (0-3.68) |
| Treatment status, n (%) | |
| Treatment naïve | 8 (9) |
| Previously treated | 85 (91) |
| Median no. of previous treatment lines (range) | 1 (1-7) |
| Current treatment regimens,∗ n (%) | |
| Immunomodulatory agent | 46 (53) |
| Corticosteroid | 40 (46) |
| Proteasome inhibitor | 35 (40) |
| Anti-CD38 monoclonal Ab | 32 (37) |
| BCMA CAR-T | 12 (14) |
| Alkylating agent | 4 (5) |
| Belantamab mafodotin | 1 (1) |
| Elotuzumab | 1 (1) |
| Hypogammaglobulinemia (IgG <400 mg/dL), n (%) | 17 (18) |
| IV immunoglobulin within 90 days, n (%) | 13 (14) |
| Comorbidities, n (%) | |
| Pulmonary disease | 10 (11) |
| Chronic kidney disease | 2 (2) |
| Diabetes | 12 (13) |
| Hypertension | 53 (57) |
| Cardiovascular disease | 6 (6) |
| Obesity (BMI >30 kg/m2) | 39 (42) |
| Current tobacco use | 0 (0) |
| Patient characteristic . | All patients (n = 93) . |
|---|---|
| Age, y | |
| Median (range) | 65 (44-84) |
| >75, n (%) | 7 (8) |
| Male sex, n (%) | 48 (52) |
| Race, n (%) | |
| White | 83 (89) |
| Non-White | 10 (11) |
| COVID-19 vaccine, n (%) | |
| BNT162b2 | 49 (53) |
| mRNA-1273 | 34 (37) |
| JNJ-78436735 | 10 (11) |
| R-ISS stage, n (%) | |
| I | 46/85 (54) |
| II | 24/85 (28) |
| III | 15/85 (18) |
| Involved heavy and/or light chain, n (%) | |
| IgG | 51 (55) |
| IgA | 16 (17) |
| κ | 61 (66) |
| λ | 24 (26) |
| Nonsecretory | 1 (1) |
| Median monoclonal protein (range), g/dL | 0.05 (0-3.68) |
| Treatment status, n (%) | |
| Treatment naïve | 8 (9) |
| Previously treated | 85 (91) |
| Median no. of previous treatment lines (range) | 1 (1-7) |
| Current treatment regimens,∗ n (%) | |
| Immunomodulatory agent | 46 (53) |
| Corticosteroid | 40 (46) |
| Proteasome inhibitor | 35 (40) |
| Anti-CD38 monoclonal Ab | 32 (37) |
| BCMA CAR-T | 12 (14) |
| Alkylating agent | 4 (5) |
| Belantamab mafodotin | 1 (1) |
| Elotuzumab | 1 (1) |
| Hypogammaglobulinemia (IgG <400 mg/dL), n (%) | 17 (18) |
| IV immunoglobulin within 90 days, n (%) | 13 (14) |
| Comorbidities, n (%) | |
| Pulmonary disease | 10 (11) |
| Chronic kidney disease | 2 (2) |
| Diabetes | 12 (13) |
| Hypertension | 53 (57) |
| Cardiovascular disease | 6 (6) |
| Obesity (BMI >30 kg/m2) | 39 (42) |
| Current tobacco use | 0 (0) |
Ab, antibody; BMI, body mass index; CAR-T, chimeric antigen receptor T-cell therapy; R-ISS, Revised Multiple Myeloma International Staging System.
Among patients who were receiving active treatment at the time of vaccination (n = 87).